## Abstract ## BACKGROUND. Significant controversy surrounds the use of remission induction chemotherapy (IC) in older adults with acute myeloid leukemia (AML). Earlier clinical trials have yielded conflicting results and possibly a minor survival benefit, often offset by a longer hospitalization
Effect of age on survival in acute leukemia: 1950–1990
✍ Scribed by Jeffery T. Sorensen; Kenneth Gerald; David Bodensteiner; Frederick F. Holmes
- Publisher
- John Wiley and Sons
- Year
- 1993
- Tongue
- English
- Weight
- 453 KB
- Volume
- 72
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
An important property of the drug arabinosyl cytosine is that the clinical effectiveness in adult acute leukemia is significantly affected by the schedule of drug administration. Moreover, changes in schedule result in a qualitative change in the nature of the dose limiting toxicity of the drug. A s
## Abstract The upper age limit for autologous stem cell transplantation (ASCT) in acute myeloid leukemia (AML) is increasing and peripheral blood (PB) represents the standard source of stem cell (SC). However, no data are available on the impact of age on SC mobilization in AML. We analyzed a coho
Serial coagulation studies were performed in 26 pediatric patients with acute lymphoblastic leukemia during initial induction therapy with vincristine, prednisone, and L-asparaginase. Prolongation of screening coagulation tests was frequent: prothrombin time (in 16 of 26 patients), partial thrombopl
Early intensive therapy might be critical in improving failure-free survival for children with acute lymphoblastic leukemia. Between 1973 and 1977, 107 children received vincristine and prednisone (VP) induction and 30 received the same two agents plus an anthracycline (VPA). Ninety-nine of the VP-t